Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In add...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/6/e006624.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864086044082176 |
|---|---|
| author | Anne Mills Leisha A Emens Mary L Disis Kunle Odunsi John B Liao Tyler Curiel Margaret Gatti-Mays Amir Jazaeri Emese Zsiros Marcus O Butler Jyoti Bajpai Katherine C Kurnit Haider Mahdi Laura Doherty Claire F Friedman Melissa A Geller Sarah F Adams Shelley A Dodt Veena S John |
| author_facet | Anne Mills Leisha A Emens Mary L Disis Kunle Odunsi John B Liao Tyler Curiel Margaret Gatti-Mays Amir Jazaeri Emese Zsiros Marcus O Butler Jyoti Bajpai Katherine C Kurnit Haider Mahdi Laura Doherty Claire F Friedman Melissa A Geller Sarah F Adams Shelley A Dodt Veena S John |
| author_sort | Anne Mills |
| collection | DOAJ |
| description | Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of disease or in other gynecologic cancers, such as ovarian cancer and rare gynecologic tumors. While the integration of ICIs into the standard of care has improved outcomes for patients, their use requires a nuanced understanding of biomarker testing, treatment selection, patient selection, response evaluation and surveillance, and patient quality of life considerations, among other topics. To address this need for guidance, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline. The Expert Panel drew on the published literature as well as their own clinical experience to develop evidence- and consensus-based recommendations to provide guidance to cancer care professionals treating patients with gynecologic cancer. |
| format | Article |
| id | doaj-art-6f1e3daea3444bceab3032c2fa552117 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-6f1e3daea3444bceab3032c2fa5521172025-02-09T08:15:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-06-0111610.1136/jitc-2022-006624Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancerAnne Mills0Leisha A Emens1Mary L Disis2Kunle Odunsi3John B Liao4Tyler Curiel5Margaret Gatti-Mays6Amir Jazaeri7Emese Zsiros8Marcus O Butler9Jyoti Bajpai10Katherine C Kurnit11Haider Mahdi12Laura Doherty13Claire F Friedman14Melissa A Geller15Sarah F Adams16Shelley A Dodt17Veena S John1819 Department of Pathology, University of Virginia Health System, Charlottesville, Virginia, USA1 Ankyra Therapeutics, Cambridge, Massachusetts, USA1 Cancer Vaccine Institute, University of Washington, Seattle, Washington, USA21 The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, USA17 University of Washington School of Medicine, Seattle, Washington, USA6 Dartmouth-Hitchcock`s Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire, USA12 Pelotonia Institute for Immuno-Oncology, Division of Medical Oncology, The Ohio State University, Columbus, Ohio, USA14 Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA20 Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA5 Department of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada3 Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India16 University of Chicago Medicine Comprehensive Cancer Center, University of Chicago, Chicago, Illinois, USA1University of Pittsburgh Medical Center, Pittsburgh, PA, USA8 Program in Women`s Oncology, Women and Infants Hospital of Rhode Island, Providence, Rhode Island, USA2Memorial Sloan Kettering Cancer Center, New York, NY, USA13 Department of Obstetrics, Gynecology & Women’s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota, USA2 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, USA7 A Cottage for Counseling, Palm City, Florida, USA15 Department of Medical Oncology & Hematology, Northwell Health Cancer Institute, Lake Success, New York, USAAdvanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of disease or in other gynecologic cancers, such as ovarian cancer and rare gynecologic tumors. While the integration of ICIs into the standard of care has improved outcomes for patients, their use requires a nuanced understanding of biomarker testing, treatment selection, patient selection, response evaluation and surveillance, and patient quality of life considerations, among other topics. To address this need for guidance, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline. The Expert Panel drew on the published literature as well as their own clinical experience to develop evidence- and consensus-based recommendations to provide guidance to cancer care professionals treating patients with gynecologic cancer.https://jitc.bmj.com/content/11/6/e006624.full |
| spellingShingle | Anne Mills Leisha A Emens Mary L Disis Kunle Odunsi John B Liao Tyler Curiel Margaret Gatti-Mays Amir Jazaeri Emese Zsiros Marcus O Butler Jyoti Bajpai Katherine C Kurnit Haider Mahdi Laura Doherty Claire F Friedman Melissa A Geller Sarah F Adams Shelley A Dodt Veena S John Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer Journal for ImmunoTherapy of Cancer |
| title | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer |
| title_full | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer |
| title_fullStr | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer |
| title_full_unstemmed | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer |
| title_short | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer |
| title_sort | society for immunotherapy of cancer sitc clinical practice guideline on immunotherapy for the treatment of gynecologic cancer |
| url | https://jitc.bmj.com/content/11/6/e006624.full |
| work_keys_str_mv | AT annemills societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT leishaaemens societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT maryldisis societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT kunleodunsi societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT johnbliao societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT tylercuriel societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT margaretgattimays societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT amirjazaeri societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT emesezsiros societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT marcusobutler societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT jyotibajpai societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT katherineckurnit societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT haidermahdi societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT lauradoherty societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT claireffriedman societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT melissaageller societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT sarahfadams societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT shelleyadodt societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer AT veenasjohn societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentofgynecologiccancer |